American Society of Hirudotherapy

Hepatic Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease (SOS/VOD) Primary Prophylaxis in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Network Meta-Analysis of Randomized Controlled Trials

Sousa-Pimenta M, Martins Â, Estevinho LM, Pinho Vaz C, Leite L, Mariz J (2024) · Journal of Clinical Medicine · n=0

RCT evidence detailTrial reference

Study Profile

Design
first network meta-analysis comparing primary prophylactic strategies against SOS/VOD in HSCT recipients (pairwise and consistent network structure)
Sample size (n)
0
Intervention
Ursodeoxycholic acid (UDCA), defibrotide, fresh frozen plasma, heparin, and other prophylactic agents against SOS/VOD
Comparator
Placebo or no prophylaxis (and pairwise between active agents)
Primary endpoint
Incidence of SOS/VOD with primary prophylaxis vs no prophylaxis or alternative
Primary result
UDCA OR 0.38 (95% CI 0.14-1.06, SUCRA 0.720) - lower SOS/VOD incidence in all HSCT recipients; defibrotide OR 0.64 (95% CI 0.23-1.67, SUCRA 0.486); in allotransplantation subgroup defibrotide OR 0.51 (SUCRA 0.650) similar to UDCA
Follow-up duration
100 days post-HSCT

Key Findings

  • First network meta-analysis of SOS/VOD prophylaxis strategies
  • UDCA emerges as most consistently effective prophylactic agent
  • Defibrotide competitive in allotransplant subgroup (SUCRA 0.650)
  • Pairwise comparisons supplemented with consistent network structure
  • Demonstrates utility of network meta-analysis for orphan complications

Limitations

  • Limited number of RCTs to include
  • Heterogeneous patient populations across trials
  • Variable SOS/VOD diagnostic criteria
  • Network inconsistency possible
  • Not applicable to whole-leech hirudotherapy

Clinical Implications

Sousa-Pimenta 2024 introduces network meta-analytic synthesis to the SOS/VOD prophylaxis evidence base. For ASH, this work demonstrates how methodologically advanced syntheses can rank competing pharmacologic strategies, distinct from the K040187 device-leech US clinical practice where comparative effectiveness research uses simpler study designs.

Related Trials

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.